Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals

Biological Chemistry

Volumn 397, Issue 1, 2016, Pages 75-83

  Wu, Shao ^a   Luo, Zhi ^a   Yu, Peng Jiu ^a   Xie, Hui ^a   He, Yu Wen ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

EMT; FOXA1; HDAC8; SAHA; TNBC

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HISTONE DEACETYLASE; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; NERVE CELL ADHESION MOLECULE; UVOMORULIN; VORINOSTAT; FOXA1 PROTEIN, HUMAN; HDAC8 PROTEIN, HUMAN; HYDROXAMIC ACID; MESSENGER RNA; REPRESSOR PROTEIN;

ARTICLE; CANCER CELL; CANCER PATIENT; CELL MIGRATION; DOWN REGULATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; WESTERN BLOTTING; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; REPRESSOR PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84950161241     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2015-0215     Document Type: Article

References (43)

1. Abramson, V.G., Lehmann, B.D., Ballinger, T.J., and Pietenpol, J.A. (2015). Subtyping of triple-negative breast cancer: implications for therapy. Cancer 121, 8-16.
2. Bauer, K.R., Brown, M., Cress, R.D., Parise. C.A., and Caggiano, V. (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109, 1721-1728.
3. Bruzzese, F., Leone, A., Rocco, M., Carbone, C., Piro, G., Caraglia, M., Di Gennaro, E., and Budillon, A. (2011). HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J. Cell Physiol. 226, 2378-2390.
4. Chen, Z.J., Yang, X.L., Liu, H., Wei, W., Zhang, K.S., Huang, H.B., Giesy, J.P., Liu, H.L., Du, J., and Wang, H.S. (2015). Bisphenol A modulates colorectal cancer protein profile and promotes the metastasis via induction of epithelial to mesenchymal transitions. Arch. Toxicol. 89, 1371-1381.
5. Deroanne, C.F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.M., Nusgens, B.V., et al. (2002). Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21, 427-436.
6. Ellis, L., Hammers, H., and Pili, R. (2009). Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 280, 145-153.
7. Hu, E., Chen, Z.X., Fredrickson, T., Zhu, Y., Kirkpatrick, R., Zhang, G.F., Johanson, K., Sung, C.M., Liu, R.G., and Winkler, J. (2000). Cloning and characterization of a novel human. Class I histone deacetylase that functions as a transcription repressor. J. Biol. Chem. 275, 15254-15264.
8. Hurtado, A., Holmes, K.A., Ross-Innes, C.S., Schmidt, D., and Carroll, J.S. (2011). FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43, 27-U42.
9. Ji, M., Lee, E.J., Kim, K.B., Kim, Y., Sung, R., Lee, S.J., Kim, D.S., and Park, S.M. (2015). HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells. Oncol. Rep. 33, 2299-2308.
10. Jiang, G.M., Wang, H.S., Zhang, F., Zhang, K.S., Liu, Z.C., Fang, R., Wang, H., Cai, S.H., and Du, J. (2013). Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression. BBA-Mol. Cell. Res. 1833, 663-671.
11. Khan, O. and La Thangue, N.B. (2012). HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 90, 85-94.
12. Kim, Y.J., Greer, C.B., Cecchini, K.R., Harris, L.N., Tuck, D.P., and Kim, T.H. (2013). HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade. Oncogene 32, 2828-2835.
13. Kirkpatrick, P. (2009). Targeting triple-negative breast cancer. Nat. Rev. Drug Discov. 8, 21.
14. Kong, D., Ahmad, A., Bao, B., Li, Y., Banerjee, S., and Sarkar, F.H. (2013). Histone deacetylase inhibitors induce epithelial-tomesenchymal transition in prostate cancer cells. PLoS One 7, e45045.
15. Lei, W.W., Zhang, K.H., Pan, X.C., Hu, Y., Wang, D.M., Yuan, X.W., Shu, G.W., and Song, J.G. (2010). Histone deacetylase 1 is required for transforming growth factor-beta 1-induced epithelial-mesenchymal transition. Int. J. Biochem. Cell Biol. 42, 1489-1497.
16. Li, D., Marchenko, N.D., and Moll, U.M. (2011). SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 18, 1904-1913.
17. Lugrin, J., Ding, X.C., Le Roy, D., Chanson, A.L., Sweep, F.C., Calandra, T., and Roger, T. (2009). Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation. Biochim. Biophys. Acta 1793, 1749-1758.
18. Luu, T.H., Morgan, R.J., Leong, L., Lim, D., McNamara, M., Portnow, J., Frankel, P., Smith, D.D., Doroshow, J.H., Wong, C., et al. (2008). A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin. Cancer Res. 14, 7138-7142.
19. Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., Shipitsin, M., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
20. Marks, P.A. (2007). Discovery and development of SAHA as an anticancer agent. Oncogene 26, 1351-1356.
21. Millikan, R.C., Newman, B., Tse, C.K., Moorman, P.G., Conway, K., Dressler, L.G., Smith, L.V., Labbok, M.H., Geradts, J., Bensen, J.T., et al. (2008). Epidemiology of basal-like breast cancer. Breast Cancer Res. Treat. 109, 123-139.
22. Mostert, B., Sleijfer, S., Foekens, J.A., and Gratama, J.W. (2009). Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat. Rev. 35, 463-474.
23. Nalls, D., Tang, S.N., Rodova, M., Srivastava, R.K., and Shankar, S. (2011). Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLos One 6, e24099.
24. OConnor, O.A., Heaney, M.L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., et al. (2006). Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24, 166-173.
25. Oehme, I., Deubzer, H.E., Wegener, D., Pickert, D., Linke, J.P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S.M., von Deimling, A., et al. (2009). Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin. Cancer Res. 15, 91-9.
26. Richon, V.M., Sandhoff, T.W., Rifkind, R.A., and Marks, P.A. (2000). Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97, 10014-10019.
27. Robinson, J.L. and Carroll, J.S. (2012). FoxA1 is a key mediator of hormonal response in breast and prostate cancer. Front. Endocrinol. (Lausanne) 3, 68.
28. Saunders, N., Dicker, A., Popa, C., Jones, S., and Dahler, A. (1999). Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. 59, 399-404.
29. Somoza, J.R., Skene, R.J., Katz, B.A., Mol, C., Ho, J.D., Jennings, A.J., Luong, C., Arvai, A., Buggy, J.J., Chi, E., et al. (2004). Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12, 1325-1334.
30. Song, Y., Washington, M.K., and Crawford, H.C. (2010). Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 70, 2115-2125.
31. Srivastava, R.K., Kurzrock, R., and Shankar, S. (2010). MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol. Cancer Ther. 9, 3254-3266.
32. Thiery, J.P., Acloque, H., Huang, R.Y.J., and Nieto, M.A. (2009). Epithelial- mesenchymal transitions in development and disease. Cell 139, 871-890.
33. Thorat, M.A., Marchio, C., Morimiya, A., Savage, K., Nakshatri, H., Reis-Filho, J.S., and Badve, S. (2008). Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J. Clin. Pathol. 61, 327-332.
34. Uchida, H., Maruyama, T., Nishikawa-Uchida, S., Oda, H., Miyazaki, K., Yamasaki, A., and Yoshimura, Y. (2012). Studies using an in vitro model show evidence of involvement of epithelial-mesenchymal transition of human endometrial epithelial cells in human embryo implantation. J. Biol. Chem. 287, 4441-4450.
35. Wei, W., Chen, Z.J., Zhang, K.S., Yang, X.L., Wu, Y.M., Chen, X.H., Huang, H.B., Liu, H.L., Cai, S.H., Du, J., et al. (2014). The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo. Cell Death Dis. 5, e1428.
36. Witt, O., Deubzer, H.E., Milde, T., and Oehme, I. (2009). HDAC family: what are the cancer relevant targets? Cancer Lett. 277, 8-21.
37. Wolf, I., Bose, S., Williamson, E.A., Miller, C.W., Karlan, B.Y., and Koeffler, H.P. (2007). FOXA1: growth inhibitor and a favorable prognostic factor in human breast cancer. Int. J. Cancer 120, 1013-1022.
38. Wu, Y., Zhang, X., Salmon, M., and Zehner, Z.E. (2007). The zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to repress vimentin gene expression. Genes Cells 12, 905-918.
39. Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., and Chen, X. (2013). Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 32, 599-609.
40. Yilmaz, M. and Christofori, G. (2009). EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis. Rev. 28, 15-33.
41. Zavadil, J. and Bottinger, E.P. (2005). TGF-beta and epithelial-tomesenchymal transitions. Oncogene 24, 5764-5774.
42. Zeisberg, M. and Neilson, E.G. (2009). Biomarkers for epithelialmesenchymal transitions. J. Clin. Invest. 119, 1429-1437.
43. Zhang, J. and Zhong, Q. (2014). Histone deacetylase inhibitors and cell death. Cell. Mol. Life Sci. 71, 3885-3901.